Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma (MRFF RCRDUN administered by La Trobe University) (2021–2025)
- Grant type:
- La Trobe University
- Researchers:
-
-
- Funded by:
- La Trobe University
